Investment Rating - The report maintains an "Outperform" rating for the company [2] Core Insights - The company achieved a revenue of 650 million yuan in H1 2025, representing a year-on-year increase of 22%, with a net profit of 171 million yuan, up 43% year-on-year [7] - The official launch of allulose marks a significant milestone, with expectations for increased sales in 2025 due to its unique properties and regulatory approvals in multiple countries [7] - The successful transformation towards high-end dietary fiber products is expected to enhance profitability, driven by the production of resistant dextrin [7] - Ongoing construction of a facility in Thailand aims to capitalize on the synthetic biology trend, further upgrading the company's product offerings [7] - The company is projected to achieve net profits of 365 million, 473 million, and 593 million yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 0.87, 1.13, and 1.41 yuan per share [7] Financial Data and Profit Forecast - Total revenue is forecasted to reach 1,716 million yuan in 2025, with a year-on-year growth rate of 49% [6] - The gross profit margin is expected to be 34% in 2025, with a return on equity (ROE) of 17.9% [6] - The company’s earnings per share (EPS) is projected to be 0.87 yuan in 2025, with a price-to-earnings (PE) ratio of 26 [6]

Investment Rating - The report maintains an "Outperform" rating for the company [1] Core Insights - The company achieved a revenue of 1.15 billion yuan in 2024, representing a year-over-year growth of 33%, and a net profit of 246 million yuan, up 27% year-over-year [4] - The first quarter of 2025 saw a revenue of 313 million yuan, a 24% increase year-over-year, and a net profit of 81 million yuan, reflecting a 52% year-over-year growth [6] - The successful launch of new production capacities for soluble dietary fiber and crystallized sugar is expected to drive sales and revenue growth [6] Financial Data and Profit Forecast - The company forecasts total revenue of 1.72 billion yuan for 2025, with a year-over-year growth rate of 49% [5] - The projected net profit for 2025 is 365 million yuan, indicating a year-over-year growth of 48.7% [5] - Earnings per share (EPS) are expected to be 1.13 yuan for 2025, with a price-to-earnings (PE) ratio of 19 [5] Investment Analysis - The company is positioned as a leading producer of health food additives in China, with significant growth potential from the upcoming approval of D-allohexose as a new food ingredient [6] - The report highlights the successful transformation towards high-end dietary fiber products, which has led to increased profitability [6] - The planned issuance of convertible bonds aims to raise up to 780 million yuan for new projects, including a health food raw material factory in Thailand [6]